Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks

Signal Transduct Target Ther. 2021 Dec 10;6(1):418. doi: 10.1038/s41392-021-00819-6.

Abstract

The systemic processes involved in the manifestation of life-threatening COVID-19 and in disease recovery are still incompletely understood, despite investigations focusing on the dysregulation of immune responses after SARS-CoV-2 infection. To define hallmarks of severe COVID-19 in acute disease (n = 58) and in disease recovery in convalescent patients (n = 28) from Hannover Medical School, we used flow cytometry and proteomics data with unsupervised clustering analyses. In our observational study, we combined analyses of immune cells and cytokine/chemokine networks with endothelial activation and injury. ICU patients displayed an altered immune signature with prolonged lymphopenia but the expansion of granulocytes and plasmablasts along with activated and terminally differentiated T and NK cells and high levels of SARS-CoV-2-specific antibodies. The core signature of seven plasma proteins revealed a highly inflammatory microenvironment in addition to endothelial injury in severe COVID-19. Changes within this signature were associated with either disease progression or recovery. In summary, our data suggest that besides a strong inflammatory response, severe COVID-19 is driven by endothelial activation and barrier disruption, whereby recovery depends on the regeneration of the endothelial integrity.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / blood*
  • Biomarkers / blood
  • Blood Proteins / metabolism*
  • C-Reactive Protein / metabolism
  • COVID-19 / diagnosis*
  • COVID-19 / immunology
  • COVID-19 / mortality
  • COVID-19 / virology
  • Chemokine CXCL10 / blood
  • Chemokine CXCL9 / blood
  • Cluster Analysis
  • Convalescence
  • Cytokine Release Syndrome / diagnosis*
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / mortality
  • Cytokine Release Syndrome / virology
  • Disease Progression
  • Endothelium, Vascular / immunology
  • Endothelium, Vascular / virology*
  • Granulocytes / immunology
  • Granulocytes / virology
  • Hematopoietic Cell Growth Factors / blood
  • Hepatocyte Growth Factor / blood
  • Humans
  • Intensive Care Units
  • Interleukin-12 Subunit p40 / blood
  • Interleukin-6 / blood
  • Interleukin-8 / blood
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / virology
  • Lectins, C-Type / blood
  • Lymphopenia / diagnosis*
  • Lymphopenia / immunology
  • Lymphopenia / mortality
  • Lymphopenia / virology
  • Plasma Cells / immunology
  • Plasma Cells / virology
  • SARS-CoV-2 / pathogenicity*
  • Survival Analysis
  • T-Lymphocytes / immunology
  • T-Lymphocytes / virology

Substances

  • Antibodies, Viral
  • Biomarkers
  • Blood Proteins
  • CLEC11A protein, human
  • CXCL10 protein, human
  • CXCL8 protein, human
  • CXCL9 protein, human
  • Chemokine CXCL10
  • Chemokine CXCL9
  • HGF protein, human
  • Hematopoietic Cell Growth Factors
  • IL6 protein, human
  • Interleukin-12 Subunit p40
  • Interleukin-6
  • Interleukin-8
  • Lectins, C-Type
  • Hepatocyte Growth Factor
  • C-Reactive Protein